Prostate cancer stem cells: from theory to practice

References

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.
   PubMed Web of Science ®Google Scholar
• Sharifi N, Dahut WL, Steinberg SM, Figg WD, Tarassoff C, Arlen P, et al. A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int 2005;96:985–9.
   PubMed Web of Science ®Google Scholar
• Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009;15:559–65.
   PubMed Web of Science ®Google Scholar
• Guzman-Ramirez N, Voller M, Wetterwald A, Germann M, Cross NA, Rentsch CA, et al. In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate 2009;69:1683–93.
   PubMed Web of Science ®Google Scholar
• Alison MR, Lim SM, Nicholson LJ. Cancer stem cells: problems for therapy? J Pathol 2011;223:147–61.
   PubMed Web of Science ®Google Scholar
• Hynes PG, Kelly K. Prostate cancer stem cells: the case for model systems. J Carcinog 2012;11:6.
   PubMedGoogle Scholar
• Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996;28:98–106.
   PubMed Web of Science ®Google Scholar
• Prajapati A, Gupta S, Mistry B. Prostate stem cells in the development of benign prostate hyperplasia and prostate cancer: emerging role and concepts. Biomed Res Int 2013;2013:107954.
   PubMed Web of Science ®Google Scholar
• van Leenders G, Dijkman H, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Lab Invest 2000;80:1251–8.
   PubMed Web of Science ®Google Scholar
• Hudson DL, O'Hare M, Watt FM, Masters JR. Proliferative heterogeneity in the human prostate: evidence for epithelial stem cells. Lab Invest 2000;80:1243–50.
   PubMed Web of Science ®Google Scholar
• Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989;2:33–50.
   PubMedGoogle Scholar
• Bidaux G, Flourakis M, Thebault S, Zholos A, Beck B, Gkika D, et al. Prostate cell differentiation status determines transient receptor potential melastatin member 8 channel subcellular localization and function. J Clin Invest 2007;117:1647–57.
   PubMed Web of Science ®Google Scholar
• Jarred RA, Cancilla B, Prins GS, Thayer KA, Cunha GR, Risbridger GP. Evidence that estrogens directly alter androgen-regulated prostate development. Endocrinology 2000;141:3471–7.
   PubMed Web of Science ®Google Scholar
• Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer 2007;7:645–58.
   PubMed Web of Science ®Google Scholar
• Schalken JA, van Leenders G. Cellular and molecular biology of the prostate: stem cell biology. Urology 2003;62:11–20.
   PubMed Web of Science ®Google Scholar
• Hudson DL. Epithelial stem cells in human prostate growth and disease. Prostate Cancer Prostatic Dis 2004;7:188–94.
   PubMed Web of Science ®Google Scholar
• Sawicki JA, Rothman CJ. Evidence for stem cells in cultures of mouse prostate epithelial cells. Prostate 2002;50:46–53.
   PubMed Web of Science ®Google Scholar
• Schmelz M, Moll R, Hesse U, Prasad AR, Gandolfi JA, Hasan SR, et al. Identification of a stem cell candidate in the normal human prostate gland. Eur J Cell Biol 2005;84:341–54.
   PubMed Web of Science ®Google Scholar
• Kwon OJ, Xin L. Prostate epithelial stem and progenitor cells. Am J Clin Exp Urol 2014;2:209–18.
   PubMedGoogle Scholar
• Blackwood JK, Williamson SC, Greaves LC, Wilson L, Rigas AC, Sandher R, et al. In situ lineage tracking of human prostatic epithelial stem cell fate reveals a common clonal origin for basal and luminal cells. J Pathol 2011;225:181–8.
   PubMed Web of Science ®Google Scholar
• Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000;157:1769–75.
   PubMed Web of Science ®Google Scholar
• English HF, Santen RJ, Isaacs JT. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 1987;11:229–42.
   PubMed Web of Science ®Google Scholar
• Leong KG, Wang BE, Johnson L, Gao WQ. Generation of a prostate from a single adult stem cell. Nature 2008;456:804–8.
   PubMed Web of Science ®Google Scholar
• Kasper S. Identification, characterization, and biological relevance of prostate cancer stem cells from clinical specimens. Urol Oncol 2009;27:301–3.
   PubMed Web of Science ®Google Scholar
• Irollo E, Pirozzi G. CD133: to be or not to be, is this the real question? Am J Transl Res 2013;5:563–81.
   PubMed Web of Science ®Google Scholar
• Collins AT, Habib FK, Maitland NJ, Neal DE. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci 2001;114:3865–72.
   PubMed Web of Science ®Google Scholar
• Heer R, Robson CN, Shenton BK, Leung HY. The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population. J Cell Physiol 2007;212:572–8.
   PubMed Web of Science ®Google Scholar
• Ousset M, Van Keymeulen A, Bouvencourt G, Sharma N, Achouri Y, Simons BD, et al. Multipotent and unipotent progenitors contribute to prostate postnatal development. Nat Cell Biol 2012;14:1131–8.
   PubMed Web of Science ®Google Scholar
• Kwon OJ, Zhang L, Ittmann MM, Xin L. Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci USA 2014;111:E592–600.
   PubMed Web of Science ®Google Scholar
• Tsujimura A, Koikawa Y, Salm S, Takao T, Coetzee S, Moscatelli D, et al. Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. J Cell Biol 2002;157:1257–65.
   PubMed Web of Science ®Google Scholar
• Goto K, Salm SN, Coetzee S, Xiong X, Burger PE, Shapiro E, et al. Proximal prostatic stem cells are programmed to regenerate a proximal-distal ductal axis. Stem Cells 2006;24:1859–68.
   PubMed Web of Science ®Google Scholar
• Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004;117:3539–45.
   PubMed Web of Science ®Google Scholar
• Alberti I, Barboro P, Barbesino M, Sanna P, Pisciotta L, Parodi S, et al. Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer. J Cell Biochem 2000;79:471–85.
   PubMed Web of Science ®Google Scholar
• Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010;17:193–9.
   PubMed Web of Science ®Google Scholar
• Moolgavkar SH, Knudson AG. Jr. Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst 1981;66:1037–52.
   PubMed Web of Science ®Google Scholar
• Sharpe B, Beresford M, Bowen R, Mitchard J, Chalmers AD. Searching for prostate cancer stem cells: markers and methods. Stem Cell Rev 2013;9:721–30.
   PubMed Web of Science ®Google Scholar
• Brawer MK. Prostatic intraepithelial neoplasia: an overview. Rev Urol 2005;7(Suppl 3):S11–8.
   PubMedGoogle Scholar
• Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res 2006;66:1883–90.
   PubMed Web of Science ®Google Scholar
• Han Z, Wang X, Ma L, Chen L, Xiao M, Huang L, et al. Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer. Oncotarget 2014;5:8416–28.
   PubMed Web of Science ®Google Scholar
• Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci USA 2011;108:1397–402.
   PubMed Web of Science ®Google Scholar
• Huels DJ, Sansom OJ. Stem vs non-stem cell origin of colorectal cancer. Br J Cancer 2015;113:1–5.
   PubMed Web of Science ®Google Scholar
• Wang ZA, Shen MM. Revisiting the concept of cancer stem cells in prostate cancer. Oncogene 2011;30:1261–71.
   PubMed Web of Science ®Google Scholar
• Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Vivienne Halili M, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009;461:495–500.
   PubMed Web of Science ®Google Scholar
• Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 2013;19:1438–49.
   PubMed Web of Science ®Google Scholar
• Grant CM, Kyprianou N. Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression. Transl Androl Urol 2013;2:202–11.
   PubMedGoogle Scholar
• Alonso-Magdalena P, Brössner C, Reiner A, Cheng G, Sugiyama N, Warner M, et al. A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc Natl Acad Sci USA 2009;106:2859–63.
   PubMed Web of Science ®Google Scholar
• Wallerand H, Robert G, Pasticier G, Ravaud A, Ballanger P, Reiter RE, et al. The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urol Oncol 2010;28:473–9.
   PubMed Web of Science ®Google Scholar
• Wang Z, Oron E, Nelson B, Razis S, Captivate N. Distinct lineage specification roles for NANOG, OCT4, and SOX2 in human embryonic stem cells. Cell Stem Cell 2012;10:440–54.
   PubMed Web of Science ®Google Scholar
• Steinestel K, Eder S, Schrader AJ, Steinestel J. Clinical significance of epithelial-mesenchymal transition. Clin Transl Med 2014;3:17.
   PubMedGoogle Scholar
• Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S, Sarkar FH. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 2010;5:e12445.
   PubMed Web of Science ®Google Scholar
• Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol 2010;41:781–93.
   PubMed Web of Science ®Google Scholar
• Li H, Tang DG. Prostate cancer stem cells and their potential roles in metastasis. J Surg Oncol 2011;103:558–62.
   PubMed Web of Science ®Google Scholar
• Borovski T, De Sousa EMF, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res 2011;71:634–9.
   PubMed Web of Science ®Google Scholar
• Psaila B, Kaplan RN, Port ER, Lyden D. Priming the 'soil' for breast cancer metastasis: the pre-metastatic niche. Breast Dis 2006;26:65–74.
   PubMedGoogle Scholar
• Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392–401.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.
   PubMed Web of Science ®Google Scholar
• Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L, et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res 2010;70:6945–56.
   PubMed Web of Science ®Google Scholar
• Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999;59:5002–11.
   PubMed Web of Science ®Google Scholar
• Wang Q, Diao X, Sun J, Chen Z. Regulation of VEGF, MMP-9 and metastasis by CXCR4 in a prostate cancer cell line. Cell Biol Int 2011;35:897–904.
   PubMed Web of Science ®Google Scholar
• Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820–7.
   PubMed Web of Science ®Google Scholar
• Schuettpelz LG, Link DC. Niche competition and cancer metastasis to bone. J Clin Invest 2011;121:1253–5.
   PubMed Web of Science ®Google Scholar
• Liao CP, Adisetiyo H, Liang M, Roy-Burman P. Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells. Cancer Res 2010;70:7294–303.
   PubMed Web of Science ®Google Scholar
• Liu A, Yu X, Liu S. Pluripotency transcription factors and cancer stem cells: small genes make a big difference. Chin J Cancer 2013;32:483–7.
   PubMed Web of Science ®Google Scholar
• Williams K, Motiani K, Giridhar PV, Kasper S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood) 2013;238:324–38.
   PubMed Web of Science ®Google Scholar
• Gu G, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007;67:4807–15.
   PubMed Web of Science ®Google Scholar
• Li H, Chen X, Calhoun-Davis T, Claypool K, Tang DG. PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res 2008;68:1820–5.
   PubMed Web of Science ®Google Scholar
• Ni J, Cozzi PJ, Hao JL, Beretov J, Chang L, Duan W, et al. CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. Prostate 2014;74:602–17.
   PubMed Web of Science ®Google Scholar
• Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44 + alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res 2007;67:6796–805.
   PubMed Web of Science ®Google Scholar
• Rowehl RA, Crawford H, Dufour A, Ju J, Botchkina GI. Genomic analysis of prostate cancer stem cells isolated from a highly metastatic cell line. Cancer Genom Proteom 2008;5:301–10.
   PubMedGoogle Scholar
• Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D, et al. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol 2013;229:355–78.
   PubMed Web of Science ®Google Scholar
• Kelly SE, Di Benedetto A, Greco A, Howard CM, Sollars VE, Primerano DA, et al. Rapid selection and proliferation of CD133+ cells from cancer cell lines: chemotherapeutic implications. PLoS One 2010;5:e10035.
   PubMed Web of Science ®Google Scholar
• Huttner WB. Prominin-1/CD133 and the cell biology of (cancer) stem cells. J Stem Cells Regen Med 2010;6:37.
   PubMedGoogle Scholar
• Williamson SC, Hepburn AC, Wilson L, Coffey K, Ryan-Munden CA, Pal D, et al. Human α(2)β(1)(HI) CD133(+VE) epithelial prostate stem cells express low levels of active androgen receptor. PLoS One 2012;7:e48944.
   PubMed Web of Science ®Google Scholar
• Vasiliou V, Pappa A, Estey T. Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. Drug Metab Rev 2004;36:279–99.
   PubMed Web of Science ®Google Scholar
• van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzmán-Ramírez N, et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 2010;70:5163–73.
   PubMed Web of Science ®Google Scholar
• Yu C, Yao Z, Jiang Y, Keller ET. Prostate cancer stem cell biology. Minerva Urol Nefrol 2012;64:19–33.
   PubMed Web of Science ®Google Scholar
• Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z, et al. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest 2010;90:234–44.
   PubMed Web of Science ®Google Scholar
• Le Magnen C, Bubendorf L, Rentsch CA, Mengus C, Gsponer J, Zellweger T, et al. Characterization and clinical relevance of ALDHbright populations in prostate cancer. Clin Cancer Res 2013;19:5361–71.
   PubMed Web of Science ®Google Scholar
• Jiao J, Hindoyan A, Wang S, Tran LM, Goldstein AS, Lawson D, et al. Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells. PLoS One 2012;7:e42564.
   PubMed Web of Science ®Google Scholar
• Lindgren AG, Natsuhara K, Tian E, Vincent JJ, Li X, Jiao J, et al. Loss of Pten causes tumor initiation following differentiation of murine pluripotent stem cells due to failed repression of Nanog. PLoS One 2011;6:e16478.
   PubMed Web of Science ®Google Scholar
• Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI. Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling. Nat Commun 2011;2:162.
   PubMed Web of Science ®Google Scholar
• Kregel S, Szmulewitz RZ, Vander Griend DJ. The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells. Prostate 2014;74:1530–43.
   PubMed Web of Science ®Google Scholar
• Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 2002;99:11890–5.
   PubMed Web of Science ®Google Scholar
• Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 2013;32:5501–11.
   PubMed Web of Science ®Google Scholar
• Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008;22:894–907.
   PubMed Web of Science ®Google Scholar
• Chen W, Wang GM, Guo JM, Sun LA, Wang H. NGF/gamma-IFN inhibits androgen-independent prostate cancer and reverses androgen receptor function through downregulation of FGFR2 and decrease in cancer stem cells. Stem Cells Dev 2012;21:3372–80.
   PubMed Web of Science ®Google Scholar
• Bidaux G, Roudbaraki M, Merle C, Crépin A, Delcourt P, Slomianny C, et al. Evidence for specific TRPM8 expression in human prostate secretory epithelial cells: functional androgen receptor requirement. Endocr Relat Cancer 2005;12:367–82.
   PubMed Web of Science ®Google Scholar
• Jeter CR, Badeaux M, Choy G, Chandra D, Patrawala L, Liu C, et al. Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 2009;27:993–1005.
   PubMed Web of Science ®Google Scholar
• Cappellari M, Bielli P, Paronetto MP, Ciccosanti F, Fimia GM, Saarikettu J, et al. The transcriptional co-activator SND1 is a novel regulator of alternative splicing in prostate cancer cells. Oncogene 2014;33:3794–802.
   PubMed Web of Science ®Google Scholar
• Guo W, Frenette PS. Alternative CD44 splicing in intestinal stem cells and tumorigenesis. Oncogene 2014;33:537–8.
   PubMed Web of Science ®Google Scholar
• Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946–51.
   PubMed Web of Science ®Google Scholar
• Sharifi N, Hurt EM, Farrar WL. Androgen receptor expression in prostate cancer stem cells: is there a conundrum? Cancer Chemother Pharmacol 2008;62:921–3.
   PubMed Web of Science ®Google Scholar
• Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR, et al. The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell 2012;10:556–69.
   PubMed Web of Science ®Google Scholar
• Maund SL, Barclay WW, Hover LD, Axanova LS, Sui G, Hipp JD, et al. Interleukin-1α mediates the antiproliferative effects of 1,25-dihydroxyvitamin D3 in prostate progenitor/stem cells. Cancer Res 2011;71:5276–86.
   PubMed Web of Science ®Google Scholar
• Rouet V, Bogorad RL, Kayser C, Kessal K, Genestie C, Bardier A, et al. Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors. Proc Natl Acad Sci USA 2010;107:15199–15204.
   PubMed Web of Science ®Google Scholar
• Lee E, Madar A, David G, Garabedian MJ, Dasgupta R, Logan SK. Inhibition of androgen receptor and β-catenin activity in prostate cancer. Proc Natl Acad Sci USA 2013;110:15710–15.
   PubMed Web of Science ®Google Scholar
• Lee SO, Ma Z, Yeh CR, Luo J, Lin TH, Lai KP, et al. New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells. J Mol Cell Biol 2013;5:14–26.
   PubMed Web of Science ®Google Scholar
• Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD, et al. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 2001;7:1273–81.
   PubMed Web of Science ®Google Scholar
• Lenz HJ, Kahn M. Safely targeting cancer stem cells via selective catenin coactivator antagonism. Cancer Sci 2014;105:1087–92.
   PubMed Web of Science ®Google Scholar
• Sastry KS, Al-Muftah MA, Li P, Al-Kowari MK, Wang E, Ismail Chouchane A, et al. Targeting proapoptotic protein BAD inhibits survival and self-renewal of cancer stem cells. Cell Death Differ 2014;21:1936–49.
   PubMed Web of Science ®Google Scholar
• Yasmin-Karim S, King MR, Messing EM, Lee YF. E-selectin ligand-1 controls circulating prostate cancer cell rolling/adhesion and metastasis. Oncotarget 2014;5:12097–110.
   PubMed Web of Science ®Google Scholar
• Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011;17:211–15.
   PubMed Web of Science ®Google Scholar
• Feldmann A, Arndt C, Topfer K, Stamova S, Krone F, Cartellieri M, et al. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells. J Immunol 2012;189:3249–59.
   PubMed Web of Science ®Google Scholar
• Arndt C, Feldmann A, Topfer K, Koristka S, Cartellieri M, Temme A, et al. Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA + prostate tumor cells. Prostate 2014;74:1347–58.
   PubMed Web of Science ®Google Scholar